Picture loading failed.

Pre-Made Nirsevimab biosimilar, Whole Mab: Anti-RSV therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nirsevimab is a passive immunisation, designed to provide RSV protection to all infants, whereby an antibody is given directly to an infant to help prevent RSV, unlike active immunisation, where a person's immune system is activated to prevent or fight infection through a vaccine.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-379-1mg 1mg 3090
GMP-Bios-ab-379-10mg 10mg 21890
GMP-Bios-ab-379-100mg 100mg 148000
GMP-Bios-ab-379-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Nirsevimab biosimilar, Whole Mab: Anti-RSV therapeutic antibody
INN Name Nirsevimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure5udc:HL:BC:EG
99% SI StructureNone
95-98% SI Structure4jha:HL/4jhw:HL
Year Proposed2018
Year Recommended2019
CompaniesAIMM Therapeutics;MedImmune
Conditions Approvedna
Conditions ActiveRespiratory syncytial virus infections
Conditions Discontinuedna
Development Techna